ProMetic Life Sciences Inc. has received a $4.8 million purchase order under its ongoing supply agreement with Octapharma, a Swiss based plasma fractionation company that specializes in human proteins. The order relates to the purchase of PrioClear, a prion capture resin incorporated into Octapharma’s manufacturing process for its solvent/detergent treated plasma product, Octaplas. Octaplas is currently approved for marketing in the U.S. and several European countries.

“This new purchase order confirms our growth forecast for shipments to Octapharma. We anticipate further growth in the coming years as they continue to gain market share in more mature markets and grow their sales in newer markets. We are pleased to see our class leading products and technologies contribute additional safety benefits to the patients,” said Mr. Pierre Laurin, president and chief executive officer of ProMetic Life Sciences.